SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

CompletedOBSERVATIONAL
Enrollment

263

Participants

Timeline

Start Date

April 30, 1994

Primary Completion Date

September 30, 2003

Study Completion Date

May 31, 2005

Conditions
LymphomaPsychosocial Effects of Cancer and Its Treatment
Interventions
PROCEDURE

psychosocial assessment and care

Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.

PROCEDURE

quality-of-life assessment

Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.

Trial Locations (11)

10003

Beth Israel Medical Center, New York

13210

State University of New York - Upstate Medical University, Syracuse

38163

University of Tennessee, Memphis Cancer Center, Memphis

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Barnes-Jewish Hospital, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

20307-5000

Walter Reed Army Medical Center, Washington D.C.

01655

University of Massachusetts Memorial Medical Center, Worcester

14263-0001

Roswell Park Cancer Institute, Buffalo

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cancer and Leukemia Group B

NETWORK

lead

SWOG Cancer Research Network

NETWORK

NCT00002563 - SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease | Biotech Hunter | Biotech Hunter